Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Neurocrine Biosciences, Inc’s stock clocked out at $128.43, up 0.03% from its previous closing price of $128.39. In other words, the price has increased by $0.03 from its previous closing price. On the day, 0.82 million shares were traded. NBIX stock price reached its highest trading level at $128.53 during the session, while it also had its lowest trading level at $126.47.
Ratios:
To gain a deeper understanding of NBIX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.06 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 24.09. For the most recent quarter (mrq), Quick Ratio is recorded 3.10 and its Current Ratio is at 3.20. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on July 21, 2025, initiated with a Buy rating and assigned the stock a target price of $163.
On July 10, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $182.
Needham Upgraded its Hold to Buy on April 15, 2025, while the target price for the stock was maintained at $138.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 10 ’25 when Delaet Ingrid sold 457 shares for $135.00 per share. The transaction valued at 61,695 led to the insider holds 4,730 shares of the business.
Onyia Jude sold 59,819 shares of NBIX for $7,803,688 on Jul 09 ’25. The Chief Scientific Officer now owns 18,289 shares after completing the transaction at $130.46 per share. On Jul 10 ’25, another insider, INGRID DELAET, who serves as the Officer of the company, bought 457 shares for $133.51 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NBIX now has a Market Capitalization of 12737880064 and an Enterprise Value of 12252081152. As of this moment, Neurocrine’s Price-to-Earnings (P/E) ratio for their current fiscal year is 37.91, and their Forward P/E ratio for the next fiscal year is 19.92. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.04. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.08 while its Price-to-Book (P/B) ratio in mrq is 4.72. Its current Enterprise Value per Revenue stands at 4.882 whereas that against EBITDA is 23.222.
Stock Price History:
The Beta on a monthly basis for NBIX is 0.28, which has changed by -0.124718845 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, NBIX has reached a high of $154.87, while it has fallen to a 52-week low of $84.23. The 50-Day Moving Average of the stock is -0.03%, while the 200-Day Moving Average is calculated to be 4.09%.
Shares Statistics:
It appears that NBIX traded 1.05M shares on average per day over the past three months and 1292260 shares per day over the past ten days. A total of 99.00M shares are outstanding, with a floating share count of 95.68M. Insiders hold about 3.54% of the company’s shares, while institutions hold 94.16% stake in the company. Shares short for NBIX as of 1752537600 were 3234044 with a Short Ratio of 3.08, compared to 1749772800 on 3495103. Therefore, it implies a Short% of Shares Outstanding of 3234044 and a Short% of Float of 4.36.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current market rating for Neurocrine Biosciences, Inc (NBIX) reflects the collective analysis of 15.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $2.35, with high estimates of $3.23 and low estimates of $2.01.
Analysts are recommending an EPS of between $8.09 and $5.79 for the fiscal current year, implying an average EPS of $6.74. EPS for the following year is $8.94, with 16.0 analysts recommending between $10.74 and $7.27.
Revenue Estimates
In the current quarter, 24 analysts expect revenue to total $749.14M. It ranges from a high estimate of $790.4M to a low estimate of $718.38M. As of the current estimate, Neurocrine Biosciences, Inc’s year-ago sales were $622.1MFor the next quarter, 24 analysts are estimating revenue of $784.32M. There is a high estimate of $852.63M for the next quarter, whereas the lowest estimate is $744.7M.
A total of 24 analysts have provided revenue estimates for NBIX’s current fiscal year. The highest revenue estimate was $2.87B, while the lowest revenue estimate was $2.71B, resulting in an average revenue estimate of $2.79B. In the same quarter a year ago, actual revenue was $2.36BBased on 23 analysts’ estimates, the company’s revenue will be $3.2B in the next fiscal year. The high estimate is $3.41B and the low estimate is $2.82B.
